BRIM-3 trial in melanoma: prognostic factors of overall survival and the issue of salvage therapies

Axel Hauschild, MD, PhD of University Hospital Schleswig-Holstein, Kiel, Germany, discusses the evaluation of long-term survival and prognostic subgroups of overall survival (OS) for the BRIM-3 trial ... Author: VJOncology Added: 09/12/2016
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts